NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) are composed of recommendations based on the best evidence available at the time they are derived. Because new data are published continuously, the NCCN Guidelines^® are constantly updated and revised to reflect evolving data. The goal of the NCCN Guidelines is to help oncologists and other oncology health care professionals make the major clinical decisions encountered in managing their patients by providing ready access to the highest quality information available based on the evaluation of expert clinicians from NCCN Member Institutions.

The NCCN Guidelines provide recommendations for appropriate care for about 95% of patients with cancer; however, individual patient circumstances must be considered when applying these recommendations. In all cases, clinicians need to be aware of the current clinical status of the patient, including general health, disease specifics, personal preference, and current and former therapies. Once the current state of the patient is known, multidisciplinary considerations, partnered with the standards of care, can be applied to each patient case. Each tumor type has specific recommendations to be considered by the multidisciplinary oncology care team.

Tumor Boards provide a forum for a multidisciplinary team of experts to review the clinical considerations and patient circumstances that influence how to effectively apply appropriate standard of care and specific recommendations in the NCCN Guidelines to optimize management of patients with various cancer types.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

The goal of this project is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to:

Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the care of patients with various cancer types.
Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the care of patients with cancer.
Communicate the importance of a multidisciplinary approach and improve the collaborative performance of the interprofessional oncology care team in the care of patients with cancer.

Additional information

Supporters:

This activity is supported by educational grants from:

AstraZeneca
Coherus BioSciences
Eisai Inc.
Genentech, a member of the Roche Group
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Novartis
Sanofi

This activity is supported by independent educational grants from:

Daiichi Sankyo
Merck & Co., Inc., Rahway, NJ, USA

This is activity is supported by independent medical education grants from:

AbbVie
GSK

Course summary

Course opens:

06/19/2024

Course expires:

06/01/2025

Cost:

$0.00

All of the live webinars in this series have concluded. The new live webinar series will start in July 2025.

The recorded webcasts from this series are listed below.

The Role of Molecular Profiling in the Management of Uterine Cancer (presented on September 4, 2024, by Natalia Buza, MD; Shari Damast, MD; and Elena Ratner, MD, MBA, Yale Cancer Center/Smilow Cancer Hospital)
Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer (presented on October 21, 2024, by Michael K. Gibson, MD, PhD, and Rajiv Agarwal, MD, MSCI, Vanderbilt-Ingram Cancer Center)
Multidisciplinary Management of Head and Neck Cancers (presented on November 14, 2024, by Sharon Spencer, MD; Lisle M. Nabell, MD; and Susan D. McCammon, MD, O'Neal Comprehensive Cancer Center at UAB)
New Approaches to Treatment of Bladder Cancer (presented on November 15, 2024, by Thomas W. Flaig, MD; Janet Kukreja, MD; and Tyler Robin, MD, PhD, University of Colorado Cancer Center)
Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer (presented January 13, 2025, by Saya L. Jacob, MD; Rachel C. Jankowitz, MD; and Igor Makhlin, MD, Abramson Cancer Center at the University of Pennsylvania)
Acute Myeloid Leukemia: The Importance of Individualized Patient Care (presented February 25, 2025, by Brion Randolph, MD, and Swapna Thota, MD; The University of Tennessee Health Science Center)
T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease (presented April 30, 2025, by L. Elizabeth Budde, MD, PhD; Lauren Clermont, DNP, NP-C, AOCNP, BMTCN; and Stacy Pak, PharmD, BCOP, City of Hope National Medical Center)
New Approaches to the Management of Resectable Non-Small Cell Lung Cancer (presented May 22, 2025, by Sandip P. Patel, MD; Kasey Bamel, DNP, FNP-BC, AOCNP; and Van Hilburn, PharmD, BCOP, MBA, UC San Diego Moores Cancer Center)
Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma (presented May 23, 2025, by Thomas G. Martin, III, MD, UCSF Helen Diller Family Comprehensive Cancer Center; Samantha Shenoy, NP, MSN, UCSF Helen Diller Family Comprehensive Cancer Center; and Rob Salmon, Patient Advocate and Co-Leader, San Francisco Bay Area Myeloma Support Group, Living with Multiple Myeloma)

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Full disclosure of faculty relationships will be made prior to the activity.

This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, case managers, and other health care professionals. Complete accreditation information is provided before each individual educational activity.

Status

Price

Title

Locked

$0.00Included

NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care